Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M

Atrium Therapeutics, Inc.

Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.
R&D expenses $16.7M, G&A $20.3M; cash and equivalents $267.8M.
ATR 1072 IND submission planned for H2 2026; pre-IND discussions with FDA/Health Canada completed.
Company launched as independent public on Feb 27, 2026 after spin-off from Avidity.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.66

Atrium Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Exhibit 99.1 Atrium Therapeutics Reports First Quarter 2026 Financial Results

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Atrium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.